More on Valeant (VRX +2.3%) Q1: Swings to net loss of $12.9M from a profit of $6.5M after taking...


More on Valeant (VRX +2.3%) Q1: Swings to net loss of $12.9M from a profit of $6.5M after taking increased provisions for restructuring and acquisition-related costs, and other charges. To buy assets from University Medical Pharmaceuticals, which focuses on skincare, for $64M and milestone payments.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs